ReviewPigment cell & melanoma research2010
Dormancy of metastatic melanoma.
Review in Pigment cell & melanoma research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 128 citations in OpenAlex.
- Early detection of metastatic risk in primary cutaneous melanoma using weakly supervised learning.Scientific reports · 2026Article
- Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases.Cancer metastasis reviews · 2025Review
- Dormancy of cutaneous melanoma.Cancer cell international · 2024Review
- Cross-scale tracing of nanoparticles and tumors at the single-cell level using the whole-lung atlas.Science advances · 2023Article
- Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.Diagnostics (Basel, Switzerland) · 2022Review
- Ferroptosis: A New Road towards Cancer Management.Molecules (Basel, Switzerland) · 2022Review
- Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors.Experientia supplementum (2012) · 2022Article
- Targeting Oncogenic GαCancers · 2021Review
- Mitochondrial Metabolism in Melanoma.Cells · 2021Review
- Initial Stage of Cutaneous Primary Melanoma Plays a Key Role in the Pattern and Timing of Disease Recurrence.Acta dermato-venereologica · 2021Article
- Rethinking the biology of metastatic melanoma: a holistic approach.Cancer metastasis reviews · 2021Review
- The State of Melanoma: Emergent Challenges and Opportunities.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Molecular Insights and Emerging Strategies for Treatment of Metastatic Uveal Melanoma.Cancers · 2020Review
- Lower Levels of Adiponectin and Its Receptor Adipor1 in the Uveal Melanomas With Monosomy-3.Investigative ophthalmology & visual science · 2020Article
- Pigmentation of conjunctival melanoma recurrences and outcome.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2019Article
- Two Late Recurrences of Conjunctival Melanoma.Ocular oncology and pathology · 2019Article
- Interleukin-23 receptor signaling mediates cancer dormancy and radioresistance in human esophageal squamous carcinoma cells via the Wnt/Notch pathway.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma.EMBO molecular medicine · 2019Article
- SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27.OncoTargets and therapy · 2019Article
- Somatostatin Receptors as Molecular Targets in Human Uveal Melanoma.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Metastatic dormancy of melanoma has not received sufficient attention, most likely because once detectable, metastasis is almost invariably fatal and, understandably, the focus has been on finding ways to prolong life of patients with overt recurrences. Nevertheless, analysis of the published clinical and experimental data on melanoma indicates that some aspect of melanoma biology imitate traits recently associated with dormancy in other solid cancers. Among them the ability of some melanomas to disseminate early during primary tumor progression and once disseminated, to remain undetected (dormant) for years. Comparison of cutaneous and uveal melanoma indicates that, in spite of being of the same origin, they differ profoundly in their clinical progression. Importantly for this discussion, between 40 and 50% of uveal melanoma remain undetected for longer than a decade, while less than 5% of cutaneous melanoma show this behavior. Both types of melanoma have activating oncogene mutations that provide autonomous pro-proliferative signals, yet the consensus is that those are not sufficient for tumor progression. If that is the case, it is possible to envision that signals from outside the tumor cell, (microenvironment) shape the fate of an individual disseminated cell, regardless of an oncogene mutation, to progress or to pause in a state of dormancy. To stimulate further debate and inquiry we describe here a few examples of potential signals that might modify the fate of disseminated cell and provide brief description of the current knowledge on dormancy in other cancers. Our hope is to convince the reader that disseminated melanoma cells do enter periods of prolonged dormancy and that finding ways to induce it, or to prolong it, might mean an extension of symptoms-free life for melanoma patients. Ultimately, understanding the biology of dormancy and the mechanisms of dormant cell survival, might allow for their specific targeting and elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.